+1 (888) 794-0077
« Return

Virtual Tours Available Today

Explore our New Jersey facilities from wherever you are working, even the comfort of your own home.

Virtually tour our New Jersey facilities in Cranbury and Plainsboro to learn about our Bioanalytical and DMPK capabilities and instrumentation to support your drug discovery and development programs.

Let’s discuss how we can help you meet your goals!

Follow WuXi AppTec Laboratory Testing Division on LinkedIn for industry insights and program support.

For more information, please visit: https://labtesting.wuxiapptec.com/


As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”

Related Posts

A New Playbook: 5 Ways to Improve Safety & Decision-Making With In Vitro Toxicology

A New Playbook: 5 Ways to Improve Safety & Decision-Making With In Vitro Toxicology

In vitro toxicology is quickly becoming the most effective way to upgrade drug development and safety programs while staying compliant with evolving regulations. What used to be viewed as “nice-to-have” early screens are now widely used to deliver faster, more human-relevant insight into potential risk, while also reducing reliance on in vivo models. Regulatory bodies worldwide have also urged a shift away from animal studies, prompting drug developers to find new ways to make smarter early decisions, protect timelines, and build clearer, more persuasive safety narratives around their compounds. Here are five ways to align your drug development program with the rapidly evolving expectations of in vitro toxicology.

IND-Ready Immunotoxicity: Four Decisions to Prevent Late Surprises

IND-Ready Immunotoxicity: Four Decisions to Prevent Late Surprises

Immune-modulating therapies, like bispecific T cell engagers (TCEs) and mRNA vaccines can be incredibly effective, but they can also trigger fast, hard-to-predict immune side effects that are costly if uncovered late in the development process. The question every team preparing for Investigational New Drug (IND) applications and first-in-human (FIH) decisions should be asking themselves is simple: How do we create an immunotoxicity strategy that is appropriate for IND submission and still executable on a real timeline?